Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial

CONCLUSION: The addition of TARE to systemic therapy for second-line CLM led to longer PFS and hPFS. Further subset analyses are needed to better define the ideal patient population that would benefit from TARE.PMID:34541864 | DOI:10.1200/JCO.21.01839

Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Mary F Mulcahy Armeen Mahvash Marc Pracht Amir H Montazeri Steve Bandula Robert C G Martin Ken Herrmann Ewan Brown Darryl Zuckerman Gregory Wilson Tae-You Kim Andrew Weaver Paul Ross William P Harris Janet Graham Jamie Mills Alfonso Yubero Esteban Matthew Source Type: research